Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Iovance Biotherapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 9.37 · gapped below the open, then crossed back over prior close. High/low 9.40 at 7:15 pm ET, 9.02 at 10:45 am ET.
Iovance Biotherapeutics, Inc. has 14 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Iovance Biotherapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Iovance Biotherapeutics, Inc.. Customers appear here when Iovance Biotherapeutics, Inc. names them, or when a company names Iovance Biotherapeutics, Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In January 2020, we obtained a license from Novartis Pharma AG, or Novartis, to develop and commercialize an antibody cytokine engrafted protein, designated as IOV-3001.”
FILING10-K0001104659-26-018899cik 0001425205
“In May 2023, as part of the Acquisition from Clinigen, we inherited a manufacturing and supply agreement with Boehringer Ingelheim Biopharmaceuticals GmbH, to carry out the processing, manufacturing, and supply of Proleukin ® in unlabeled vials through October 2025.”
FILING10-K0001104659-26-018899cik 0001425205
“We have a Cooperative Research and Development Agreement, or CRADA, with the NCI for the development of adoptive cell immunotherapies in multiple solid tumor types, including bladder, lung, and triple-negative breast cancers; Human Papilloma Virus, or HPV, associated cancers and a broad range of epithelial cancers.”
FILING10-K0001104659-26-018899cik 0001425205
“We entered into a patent license agreement, or the Patent License Agreement, with the NIH in 2011.”
FILING10-K0001104659-26-018899cik 0001425205
“In November 2016, we entered manufacturing services agreements, or MSAs, with WuXi Advanced Therapies, Inc., and its parent company WuXi Apptec, Co. Ltd (collectively, "WuXi").”
FILING10-K0001104659-26-018899cik 0001425205
“In May 2023, we acquired the worldwide rights to Proleukin ® from Clinigen Holdings Limited, Clinigen Healthcare Limited, and Clinigen, Inc., which we refer to collectively as Clinigen.”
FILING10-K0001104659-26-018899cik 0001425205
“On August 22, 2025, we entered into an Amended and Restated Open Market Sale Agreement, or the 2025 Sale Agreement, with Jefferies with respect to an "at the market" offering program.”
FILING10-K0001104659-26-018899cik 0001425205
“Additionally, we partner with American Red Cross, or ARC, to operate our facility to produce feeder cells for TIL manufacturing.”
FILING10-K0001104659-26-018899cik 0001425205
“For example, BI carries out the processing, manufacturing, and supply of Proleukin ® pursuant to a manufacturing and supply agreement, which includes a two-year notice of termination provision.”
FILING10-K0001104659-26-018899cik 0001425205
“We are required to pay substantial royalties and lump sum benchmark payments under our license or acquisition agreements with the NIH, Novartis, Clinigen, and Cellectis, and we must meet certain milestones to maintain our license rights;”
FILING10-K0001104659-26-018899cik 0001425205
“In December 2019, we entered into a research collaboration and exclusive worldwide license agreement for gene-editing technology from Cellectis, a clinical-stage biopharmaceutical company, to develop genetically edited TIL cell therapies, including a PD-1 inactivated product that we refer to as IOV-4001.”
FILING10-K0001104659-26-018899cik 0001425205
“We are required to pay substantial royalties and lump sum benchmark payments under our license or acquisition agreements with the NIH, Novartis, Clinigen, and Cellectis, and we must meet certain milestones to maintain our license rights;”
FILING10-K0001104659-26-018899cik 0001425205
“Currently our products and product candidates are manufactured internally at the i CTC and previously externally by Minaris Advanced Therapies, Inc., or Minaris, and the H. Lee Moffitt Cancer Center, or Moffitt.”
FILING10-K0001104659-26-018899cik 0001425205
“Currently our products and product candidates are manufactured internally at the i CTC and previously externally by Minaris Advanced Therapies, Inc., or Minaris, and the H. Lee Moffitt Cancer Center, or Moffitt.”
FILING10-K0001104659-26-018899cik 0001425205
Watchlist prices, news filtered to it, and its next report on your desk.
IOVA (Iovance Biotherapeutics, Inc.) has 14 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: JEF −2.47%, in financials.